Cargando…
EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides
The skeleton is the most common metastatic site in patients with advanced cancer. Pain is a major healthcare problem in patients with bone metastases. Bone-seeking radionuclides that selectively accumulate in the bone are used to treat cancer-induced bone pain and to prolong survival in selected gro...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978928/ https://www.ncbi.nlm.nih.gov/pubmed/29453701 http://dx.doi.org/10.1007/s00259-018-3947-x |
_version_ | 1783327585473658880 |
---|---|
author | Handkiewicz-Junak, Daria Poeppel, Thorsten D. Bodei, Lisa Aktolun, Cumali Ezziddin, Samer Giammarile, Francesco Delgado-Bolton, Roberto C. Gabriel, Michael |
author_facet | Handkiewicz-Junak, Daria Poeppel, Thorsten D. Bodei, Lisa Aktolun, Cumali Ezziddin, Samer Giammarile, Francesco Delgado-Bolton, Roberto C. Gabriel, Michael |
author_sort | Handkiewicz-Junak, Daria |
collection | PubMed |
description | The skeleton is the most common metastatic site in patients with advanced cancer. Pain is a major healthcare problem in patients with bone metastases. Bone-seeking radionuclides that selectively accumulate in the bone are used to treat cancer-induced bone pain and to prolong survival in selected groups of cancer patients. The goals of these guidelines are to assist nuclear medicine practitioners in: (a) evaluating patients who might be candidates for radionuclide treatment of bone metastases using beta-emitting radionuclides such as strontium-89 ((89)Sr), samarium-153 ((153)Sm) lexidronam ((153)Sm-EDTMP), and phosphorus-32 ((32)P) sodium phosphate; (b) performing the treatments; and ©) understanding and evaluating the treatment outcome and side effects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-018-3947-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5978928 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-59789282018-06-21 EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides Handkiewicz-Junak, Daria Poeppel, Thorsten D. Bodei, Lisa Aktolun, Cumali Ezziddin, Samer Giammarile, Francesco Delgado-Bolton, Roberto C. Gabriel, Michael Eur J Nucl Med Mol Imaging Guidelines The skeleton is the most common metastatic site in patients with advanced cancer. Pain is a major healthcare problem in patients with bone metastases. Bone-seeking radionuclides that selectively accumulate in the bone are used to treat cancer-induced bone pain and to prolong survival in selected groups of cancer patients. The goals of these guidelines are to assist nuclear medicine practitioners in: (a) evaluating patients who might be candidates for radionuclide treatment of bone metastases using beta-emitting radionuclides such as strontium-89 ((89)Sr), samarium-153 ((153)Sm) lexidronam ((153)Sm-EDTMP), and phosphorus-32 ((32)P) sodium phosphate; (b) performing the treatments; and ©) understanding and evaluating the treatment outcome and side effects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-018-3947-x) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-02-16 2018 /pmc/articles/PMC5978928/ /pubmed/29453701 http://dx.doi.org/10.1007/s00259-018-3947-x Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Guidelines Handkiewicz-Junak, Daria Poeppel, Thorsten D. Bodei, Lisa Aktolun, Cumali Ezziddin, Samer Giammarile, Francesco Delgado-Bolton, Roberto C. Gabriel, Michael EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides |
title | EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides |
title_full | EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides |
title_fullStr | EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides |
title_full_unstemmed | EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides |
title_short | EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides |
title_sort | eanm guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides |
topic | Guidelines |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978928/ https://www.ncbi.nlm.nih.gov/pubmed/29453701 http://dx.doi.org/10.1007/s00259-018-3947-x |
work_keys_str_mv | AT handkiewiczjunakdaria eanmguidelinesforradionuclidetherapyofbonemetastaseswithbetaemittingradionuclides AT poeppelthorstend eanmguidelinesforradionuclidetherapyofbonemetastaseswithbetaemittingradionuclides AT bodeilisa eanmguidelinesforradionuclidetherapyofbonemetastaseswithbetaemittingradionuclides AT aktoluncumali eanmguidelinesforradionuclidetherapyofbonemetastaseswithbetaemittingradionuclides AT ezziddinsamer eanmguidelinesforradionuclidetherapyofbonemetastaseswithbetaemittingradionuclides AT giammarilefrancesco eanmguidelinesforradionuclidetherapyofbonemetastaseswithbetaemittingradionuclides AT delgadoboltonrobertoc eanmguidelinesforradionuclidetherapyofbonemetastaseswithbetaemittingradionuclides AT gabrielmichael eanmguidelinesforradionuclidetherapyofbonemetastaseswithbetaemittingradionuclides |